61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Amgen Inc
Closed
Sector Healthcare
277.5 1.86
Overview
Share price change
24h
Min
271.64
Max
279.72
Income | 2.1B 2.8B |
|---|---|
Sales | 110M 8.5B |
P/E Sector Avg | 44.64 94.904 |
EPS | 5.58 |
Dividend yield | 2.793 |
Profit margin | 33.294 |
Employees | 26,700 |
EBITDA | 441M 3.4B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +24.67 upside |
Dividend yield Sector Avg | 2.79% 2.43% |
|---|---|
Next Earnings | 4 Feb 2025 |
Next Dividend date | 6 Mar 2025 |
Next Ex Dividend date | 13 Feb 2025 |
Market Cap | -699M 150B |
|---|---|
Previous open | 275.64 |
Previous close | 277.5 |
News Sentiment
By Acuity
39%
61%
149 / 392 Healthcare
Technical Score
By Trading Central
Confidence
Neutral Evidence
Amgen Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Amgen Inc Forecast
Price Target
By TipRanks
24.67% upside
12 Months Forecast
Average 339.83 USD 24.67%
High 405 USD
Low 215 USD
Based on 23 Wall Street analysts offering 12 month price targets forAmgen Inc - Dist in the last 3 months.
Sentiment
By Acuity
149 / 392 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Amgen Inc
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
